 LA JOLLA, Calif., Nov. 25, 2020 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that positive Optical Coherence Tomography OCT results from the SPRINT-MS Phase 2b trial of MN-166 ibudilast in progressive multiple sclerosis progressive MS were published in Multiple Sclerosis Journ al. OCT was a secondary outcome measure in the SPRINT-MS trial. 